The road to becoming green: Process development of AR-A2, an active pharmaceutical ingredient with antidepressant activity

Scalable Green Chemistry: Case Studies from the Pharmaceutical Industry

Volumn , Issue , 2013, Pages 105-135

  Federsel, Hans Jürgen ^a   Hedberg, Martin ^a   Qvarnström, Fredrik R ^a   Tian, Wei ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; PROCESS DEVELOPMENT;

EID: 84886384170     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814364812     Document Type: Chapter

References (51)

1. Mours, M. (2008). ChemSusChem, 1, 59-62.
2. Anastas, P. T.;Warner, J. C. (1998). Green Chemistry: Theory and Practice Oxford University Press.
3. Anastas, P. T.; Kirchhoff, M. M (2002). Acc. Chem. Res., 35, 686-694.
4. Tucker, J. L. (2006). Org. Process Res. Dev., 10, 315-319.
5. Federsel, H.-J. (2003). Nat. Rev. Drug Discov., 2, 654-664.
6. Federsel, H.-J. (2003). Curr. Opin. Drug Discov. Dev., 6, 838-847.
7. Federsel, H.-J. (2006). Drug Discov. Today, 11, 966-974.
8. Federsel, H.-J. (2009). Acc. Chem. Res., 42, 671-680.
9. Clark, J. H.; Tavener, S. J. (2007). Org. Process Res. Dev., 11, 149-155.
10. Federsel, H.-J.; Hedberg, M.; Qvarnström, F. R.; Sjögren, M. P. T.; Tian, W. (2007). Acc. Chem. Res., 40, 1377-1384.
11. Federsel, H.-J.; Hedberg, M.; Qvarnström, F. R.; Tian W. (2008). Org. Process Res. Dev., 12, 512-521.
12. Federsel, H.-J. (2010). Bioorg. Med. Chem., 18, 5775-5794.
13. Stenfors, C.; Ahlgren, C.; Yu, H.; Larsson, L.-G.; Ross, S. B. (2004). Psychopharmacology, 172, 333-340.
14. Stenfors, C.; Hallerbäck, T.; Larsson, L.-G.;Wallsten, C.; Ross, S. B. (2004). Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 330-337.
15. Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H. (1981). J. Med. Chem., 24, 921-923.
16. Mason, J. P.; Dring, L. G.; Caldwell, J. (1995). Xenobiotica, 25, 1371-1380.
17. Sari, Y. (2004). Neurosci. Biobehav. Rev., 28, 565-582.
18. Berg, S.; Linderberg, M.; Ross, S. B.; Thorberg, S.-O; Ulff, B. (1999). PCT Int. Appl.WO 9905,134.
19. Levy, A. A.; Rains H. C.; Smiles, S. (1931). J. Chem. Soc., 3264-3269.
20. Evans,W. J.; Smiles, S. (1935). J. Chem. Soc., 181-188.
21. Sommers, A. H.; Barnes, J. D. (1955). J. Am. Chem. Soc., 77, 4171-4172.
22. Süsse, M.; Skubatz, R.; Demus, D.; Zaschke, H. (1986). J. Prakt. Chem., 328, 349-358.
23. Guram, A. S.; Rennels, R. A.; Buchwald, S. L. (1995). Angew. Chem. Int. Ed. Engl., 34, 1348-1350.
24. Louie, J.; Hartwig, J. F. (1995). Tetrahedron Lett., 36, 3609-3612.
25. Tian, W. (2001). PCT Int. Appl.WO 01/87865.
26. Celgene Corp., P. O. Box 4914, 7 Powder Horn Drive, Warren, NJ 07059, USA.
27. Stirling, D. I.; Zeitlin, A. L.; Matcham, G. W. (1990). Enantiomeric Enrichment and Stereoselective synthesis of Chiral Amines, US Patent 4,950,606.
28. Rajšner, M.; Svátek, E.; Metyšová, J.; Bartošová, M.; Mikšik, F.; Protiva, M. (1977). Collect. Czech. Chem. Commun., 42, 3079-3093.
29. Sims, J. J.; Selman, L. H.; Cadogan, M. (1971). Org. Synth., 51, 109-112.
30. Hunden, D. C. (1984). Org. Prep. Proc. Int., 16, 294-297.
31. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.;Maryanoff, C. A.; Shah, R. D. (1996). J. Org. Chem., 61, 3849-3862.
32. Soloshonok, V. A.; Ono, T.; Soloshonok, I. V. (1997). J. Org. Chem., 62, 7538-7539.
33. Zhong, H. M.; Cohen, J. H.; Abdel-Magid, A. F.; Kenney, B. D.; Maryanoff, C. A.; Shah, R. D.; Villani, F. J., Jr.; Zhang, F.; Zhang, X. (1999). Tetrahedron Lett., 40, 7721-7725.
34. Knupp, G.; Frahm, A.W. (1984). Chem. Ber., 117, 2076-2098.
35. Eleveld, M. B.; Hogeveen, H. (1984). Tetrahedron Lett., 25, 5187-5190.
36. Kanai, Y.; Saitou, K.; Koki, U. (1998). Jpn. Kokai Koho 10 072 411.
37. Constable, D. J. C.; Curzons, A. D.; Cunningham, V. L. (2002). Green Chem., 4, 521-527.
38. Sheldon, R. A. (2007). Green Chem., 9, 1273-1283.
39. Greene, T.W.;Wuts, P. G. M. (1999) Protective Groups in Organic Synthesis (3rd ed.). New York, NY: Wiley, 579-580.
40. Degutiene, A.; Rasteikiene, L.; Degutis, J. (1976). 4-Morpholinophenylalkanoic Acids, Soviet Union Patent 510475 (in Russian).
41. Degutis, J.; Rasteikiene, L.; Degutiene, A. (1978). Z. Org. Khim. (J. Org. Chem. USSR), 14, 2060-2064.
42. Setti, E. L.; Davis, D.; Janc, J. W.; Jeffery, D. A.; Cheung, H.; Yu, W. (2005). Bioorg. Med. Chem. Lett., 15, 1529-1534.
43. Wolfe, J. P.; Buchwald, S. L. (1997). J. Org. Chem., 62, 1264-1267.
44. Louie, J.; Driver, M. S.; Hamann, B. C.; Hartwig, J. F. (1997). J. Org. Chem., 62, 1268-1273.
45. Kotsuki, H.; Kobayashi, S.; Suenaga, H.; Nishizawa, H. (1990). Synthesis, 1145-1148.
46. Brown, G. R.; Foubister, A. J.; Ratcliffe, P. D. (1999). Tetrahedron Lett., 40, 1219-1222.
47. Merck & Co. (1996). Entry 4948 "Imidazole," in The Merck Index (12th ed.). Merck & Co., 844.
48. Allain Lorié, V. (2002). Unpublished results (AstraZeneca).
49. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2009) Impurities: Guideline for Residual Solvents Q3C(R4). http://www.ich.org/cache/compo/276-254-1.html (accessed August 16, 2010).
50. Merck & Co. (1996). Entry 7780 "Potassium Bromide," in The Merck Index (12th ed.). Merck & Co., 1313.
51. Ban, T. A. (2001). Prog. Neuro-Psychopharmacol. Biol. Psychiat., 25, 709-727.